1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW)

1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW)

Bibliographic Details
Main Authors: Victoria P Werth, Eric F Morand, Melinda Przetak, Flavie Moreau, Cristina Vazquez-Mateo, Andrew Bender, Sanjeev Roy, Aditee Deshpande, Ankita Deshmukh, Bharat Vaidyanathan, Mukhy Khursheed, David R Pearson
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Lupus Science and Medicine

Similar Items